AP2000001917A0 - Gene encoding labyrinthin, a marker for cancer. - Google Patents

Gene encoding labyrinthin, a marker for cancer.

Info

Publication number
AP2000001917A0
AP2000001917A0 APAP/P/2000/001917A AP2000001917A AP2000001917A0 AP 2000001917 A0 AP2000001917 A0 AP 2000001917A0 AP 2000001917 A AP2000001917 A AP 2000001917A AP 2000001917 A0 AP2000001917 A0 AP 2000001917A0
Authority
AP
ARIPO
Prior art keywords
lab
cancers
cancer
protein
labyrinthin
Prior art date
Application number
APAP/P/2000/001917A
Other languages
English (en)
Inventor
James A Radosevich
Original Assignee
Immvarx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immvarx Inc filed Critical Immvarx Inc
Publication of AP2000001917A0 publication Critical patent/AP2000001917A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
APAP/P/2000/001917A 1998-03-17 1999-03-11 Gene encoding labyrinthin, a marker for cancer. AP2000001917A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/040,485 US6166176A (en) 1998-03-17 1998-03-17 Cancer marker protein and peptides thereof
PCT/US1999/005365 WO1999047683A1 (en) 1998-03-17 1999-03-11 Gene encoding labyrinthin, a marker for cancer

Publications (1)

Publication Number Publication Date
AP2000001917A0 true AP2000001917A0 (en) 2000-09-30

Family

ID=21911225

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2000/001917A AP2000001917A0 (en) 1998-03-17 1999-03-11 Gene encoding labyrinthin, a marker for cancer.

Country Status (14)

Country Link
US (7) US6166176A (enExample)
EP (1) EP1062346B1 (enExample)
JP (2) JP2002512005A (enExample)
CN (2) CN101260401A (enExample)
AP (1) AP2000001917A0 (enExample)
AT (1) ATE337400T1 (enExample)
AU (2) AU762758B2 (enExample)
BR (1) BR9908886A (enExample)
CA (1) CA2323494A1 (enExample)
DE (1) DE69932926T2 (enExample)
EA (1) EA003735B1 (enExample)
IL (1) IL138208A0 (enExample)
OA (1) OA11487A (enExample)
WO (1) WO1999047683A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166176A (en) * 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
US6835370B2 (en) * 1999-11-08 2004-12-28 Rhode Island Hospital Diagnosis and treatment of malignant neoplasms
US20030031670A1 (en) * 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
US20050123545A1 (en) * 1999-11-08 2005-06-09 Wands Jack R. Diagnosis and treatment of malignant neoplasms
US6682902B2 (en) * 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
US7306919B1 (en) 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
JP2006502110A (ja) * 2002-07-03 2006-01-19 イミュノジェン・インコーポレーテッド 非放出Ｍｕｃ１およびＭｕｃ１６に対する抗体、およびその使用
DK1512695T3 (da) * 2003-09-04 2009-03-16 Biomay Ag Hypoallergeniske polypeptider på fiske-parvalbumin
US7413737B2 (en) * 2003-11-14 2008-08-19 Massachusetts Institute Of Technology Anti-hydroxylase antibodies and uses thereof
CN100457922C (zh) * 2005-10-20 2009-02-04 康哲医药研究(深圳)有限公司 检测酪丝亮肽抗肝癌效果的方法及所用试剂盒与基因芯片
RU2340896C1 (ru) * 2007-05-17 2008-12-10 Негосударственное научно-исследовательское учреждение "Биомедицинский центр" Способ диагностики онкологических заболеваний
GB201002627D0 (en) 2010-02-16 2010-03-31 Loxbridge Res Llp Aptamer based analyte detection method
WO2020123964A1 (en) * 2018-12-13 2020-06-18 Labyrx Immunologic Therapeutics (Usa) Limited Labyrinthin-based peptides for cancer immunotherapies and uses thereof
CN113993892A (zh) * 2019-01-08 2022-01-28 莱比锡免疫治疗(美国)有限公司 靶向迷路蛋白或其部分的构建体以及所述构建体的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816402A (en) * 1986-01-07 1989-03-28 Northwestern University Murine hybridoma and diagnostic antibody produced thereby
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5223604A (en) * 1991-06-25 1993-06-29 S.P.I. Synthetic Peptides Incorporated Pseudomonas exoenzyme s peptide composition and method
US5728819A (en) * 1996-08-02 1998-03-17 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
US5994062A (en) 1995-10-02 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Epithelial protein and DNA thereof for use in early cancer detection
US6166176A (en) 1998-03-17 2000-12-26 Immvarx, Inc. Cancer marker protein and peptides thereof
US6344548B1 (en) * 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
US7135617B2 (en) * 1998-07-02 2006-11-14 Calgene Llc Diacylglycerol acyl transferase proteins
US6100077A (en) * 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
US7045326B2 (en) * 2001-02-23 2006-05-16 The Regents Of The University Of California Mono- and diacylglycerol acyltransferases and methods of use thereof
US20030161831A1 (en) * 2001-02-23 2003-08-28 Sylvaine Cases Mono-and diacylglycerol acyltransferases and methods of use thereof
CA2492205A1 (en) * 2002-07-31 2004-02-05 Monsanto Technology, Llc Diacylglycerol acyltransferase nucleic acid sequences and associated products
US8685679B2 (en) * 2004-11-04 2014-04-01 E I Du Pont De Nemours And Company Acyltransferase regulation to increase the percent of polyunsaturated fatty acids in total lipids and oils of oleaginous organisms
US8507754B2 (en) * 2009-01-31 2013-08-13 University Of North Texas Engineering lipids in vegetative tissues of plants
CA2804025C (en) * 2010-06-28 2023-02-21 Commonwealth Scientific And Industrial Research Organisation Methods of producing lipids

Also Published As

Publication number Publication date
BR9908886A (pt) 2000-11-21
US20100233711A1 (en) 2010-09-16
HK1033151A1 (en) 2001-08-17
US7329743B2 (en) 2008-02-12
EP1062346A1 (en) 2000-12-27
AU762758B2 (en) 2003-07-03
EA200000845A1 (ru) 2001-08-27
US6166176A (en) 2000-12-26
CA2323494A1 (en) 1999-09-23
US8163883B2 (en) 2012-04-24
JP2002512005A (ja) 2002-04-23
US20100112582A1 (en) 2010-05-06
US20110110963A1 (en) 2011-05-12
AU2003204331B2 (en) 2008-02-07
US6727080B1 (en) 2004-04-27
IL138208A0 (en) 2001-10-31
AU2999699A (en) 1999-10-11
DE69932926T2 (de) 2007-05-24
OA11487A (en) 2004-05-04
CN101260401A (zh) 2008-09-10
EA003735B1 (ru) 2003-08-28
US7635759B2 (en) 2009-12-22
ATE337400T1 (de) 2006-09-15
US20080249284A1 (en) 2008-10-09
CN100372938C (zh) 2008-03-05
WO1999047683A1 (en) 1999-09-23
CN1301302A (zh) 2001-06-27
US20050208508A1 (en) 2005-09-22
DE69932926D1 (de) 2006-10-05
EP1062346B1 (en) 2006-08-23
JP2009165492A (ja) 2009-07-30
WO1999047683A9 (en) 1999-11-18

Similar Documents

Publication Publication Date Title
Anichini et al. Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2. 1-restricted immune repertoire to melanoma
NZ331866A (en) Compounds for immunotherapy and immunodiagnosis of prostate cancer
Marcaurelle et al. Chemical synthesis of lymphotactin: a glycosylated chemokine with a C‐terminal mucin‐like domain
Kemp et al. Autoantibodies to human melanocyte-specific protein Pmel17 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA)
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
BR0012069A (pt) Composições e métodos para a terapia e diagnóstico de câncer pulmonar
AU2001253079A1 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
BR9917218A (pt) Anticorpos monoclonais, antìgenos, e diagnósticoe terapia de doenças malignas
WO2002008262A3 (en) Bstp-5 proteins and related reagents and methods of use thereof
WO1998010069A3 (en) E25a protein, methods for production and use thereof
BR9912007A (pt) Composições e métodos para terapia e diagnóstico de câncer de próstata
BR0009537A (pt) Composições para tratamento e diagnóstico de câncer de mama e métodos para seu uso
EP1006194A3 (en) C-erbB-2 external domain: GP75
SE9500023D0 (sv) Method of detecting cancer
WO2002083070A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
ATE106940T1 (de) Für das polypeptid des t-zellantigenreceptors kodierende nukleinsäure.
ATE198513T1 (de) Ptpalpha-bestimmung in der tumordiagnose und - prognose
EA200000845A1 (ru) Ген, кодирующий новый маркер рака
PT1034185E (pt) Composicoes farmaceuticas que contem a pentraxina longa ptx3
WO1992015602A1 (en) Cancer diagnosis and therapy
EP1270745A3 (en) Thymosin B15 as a marker in diagnosis and prognosis of cancer
DE60032784D1 (de) Markerproteine für prostatakrebs
EP1005539A4 (en) IKK-ALPHA PROTEINS, NUCLEIC ACIDS AND METHOD
DE69126038D1 (de) Diagnose von krebs-metastasen durch das mts-1 gen
Burger Pathology of brain stem astrocytomas